NCT02066454 2025-08-13
MYELAXAT
University Hospital, Grenoble
Phase 3 Completed
Clinical Trials
19 trialsNCT03045406 2025-06-24
CARAVAGGIO
Fadoi Foundation, Italy
Phase 3 Completed
NCT03080883 2025-05-18
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Academic and Community Cancer Research United
Phase 3 Completed
NCT03692065 2025-02-06
API-CAT
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT04243122 2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2 Completed
NCT02744092 2023-10-03
CANVAS
Alliance Foundation Trials, LLC.
Phase NA Completed
NCT05461807 2022-10-26
H2H-OSCAR-US
Bayer
Completed
NCT01999179 2022-05-18
Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
Medical College of Wisconsin
Phase NA Completed
NCT02369653 2022-03-08
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
Bristol-Myers Squibb
Phase 3 Completed
NCT04191928 2021-12-23
PAP-UP
Thomas Jefferson University
Phase 1 Completed
NCT03965741 2021-11-30
PRACTISE
Bayer
Completed
NCT04192916 2021-02-21
MPN-DOACs
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Completed
NCT02585713 2020-08-04
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United
Phase 3 Completed
NCT02366871 2020-03-31
Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
University of Colorado, Denver
Phase 2 Completed
NCT02958969 2019-12-17
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
Dana-Farber Cancer Institute
Phase 4 Completed
NCT02048865 2018-11-20
AVERT
Ottawa Hospital Research Institute
Phase 2 Completed
NCT02581176 2018-06-26
CAP
University Hospital, Akershus
Phase 4 Completed
NCT03083782 2017-10-11
ACT
Thomas Jefferson University
Phase 1 Completed
NCT00320255 2016-08-16
A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
Bristol-Myers Squibb
Phase 2 Completed